Epitranscriptomics-Driven and Computationally Enhanced Proteins for Human Health and Nutrition

Cells uniquely adapt to stressors to reprogram mRNA translation and protein expression. We have cracked this alternative genetic and epitranscriptomic linked code.

Our Epi-MAX platform is an integrated suite of omics tools that reprograms cells to achieve efficient biomanufacturing of difficult-to-express proteins.

Our Mission

To enable highly efficient and low-cost production of difficult-to-express bio-industrial and cellular agriculture proteins with retention of their nature-identical properties.

Our Vision

Sustainable production of therapeutics and alternative foods that are accessible and affordable to all populations for the betterment of global health and nutrition.

News

Codomax, in collaboration with the lab of Prof. Stephen Fried at The Johns Hopkins University, has been awarded a third phase I STTR grant from NIH/NCATS to leverage the Epi-MAX platform's tRNA-centric strain engineering approach to engineer Pichia strains to enhance proper folding and assembly of secreted recombinant proteins.

Codomax, in collaboration with the labs of Prof. Susan Sharfstein and Prof. Tom Begley at the University at Albany, has been awarded a second Phase I STTR grant from NIH/NCATS to apply the Epi-MAX platform to optimize antibody produciton in CHO cells..

Codomax has been awarded a Phase I STTR grant from NIH/NCATS to apply the Epi-MAX platform to the production of interferon biologics.

              The Epi-MAX Platform:                            tRNA-Centric Engineering

Environmental and physiological stresses reprogram cells' epitranscriptomes and proteomes. We exploit this mechanism to unlock cells' potential for 
producing complex and difficult-to-express proteins by:

  1. Systems-level, omics-based measurements of the cell's stress response
  2. Computational analysis of how cells adapt their translational machinery
  3. Re-engineering cells and their genes to maximize protein yields in response to the stresses associated with their biomanufacturing conditions

Applications of Our Epi-MAX Platform

Why ?

Our Differentiating Factors

 
Flexible
We work with any cell type and production conditions
Versatile
Our Epi-MAX platform is plug and play with complementary technologies
Empirical
Our platform engineers based on real-time biology, not predictive models
Epitranscriptome-centric
We engineer based on a cell's pool of tRNAs & tRNA modifications
Data-Driven
Our software is guided by data collected from systems-level experimental measurements
Coordinated
Our approach harmonizes a cell's biology to function optimally under its environmental conditions & stressors

Why ?

Our Differentiating Factors

 
Flexible
We work with any cell type and production conditions
Versatile
Our Epi-MAX platform is plug and play with complementary technologies
Empirical
Our platform engineers based on real-time biology, not predictive models
Epitranscriptome-centric
We are engineering based on tRNA levels & modifications, not just codons
Data-Driven
Our software is guided by data collected from systems-level experimental measurements
Adaptive
Our approach harmonizes a cell's biology to function optimally under its environmental conditions & stressors

Our Team

We are scientists, engineers, and entrepreneurs from MIT and The RNA Institute with an extensive track record of discoveries and publications related to stress-induced reprogramming of cells and their epitranscriptomes. We are determined to apply our expertise to solve universal issues that plague protein manufacturing in order to make biologics and cellular agriculture proteins affordable and accessible to all.

 

Joseph Reddy, Ph.D.
President and CEO

Shane Byrne, Ph.D.
Co-Founder and CSO

Peter Dedon, M.D., Ph.D.
Co-Founder and Advisor

Thomas Begley, Ph.D.
Co-Founder and Advisor

E-Ming Rau, Ph.D.
Research Scientist

Our Team

We are scientists, engineers, and entrepreneurs from MIT and The RNA Institute with an extensive track record of discoveries and publications related to stress-induced reprogramming of cells and their epitranscriptomes. We are determined to apply our expertise to solve universal issues that plague protein manufacturing in order to make these biologics and cellular agriculture proteins affordable and accessible to all.

 

Joseph Reddy, Ph.D.
President and CEO

Shane Byrne, Ph.D.
Co-Founder and CSO

Peter Dedon, M.D., Ph.D.
Co-Founder and Advisor

Thomas Begley, Ph.D.
Co-Founder and Advisor

E-Ming Rau, Ph.D.
Research Scientist


Contact Us

Interested in working with us or learning more about us?

Reach out to us on LinkedIn.


 
We are located at the Massachusetts Biomedical Initiatives (MBI):

17 Briden St
STE 220
Worcester, MA 01605